Sabine Mueller, MD,PhD

CHAIRPERSON

PEDIATRIC NEURO ONCOLOGY
UCSF BENIOFF CHILDREN’S HOSPITAL

Sabine Mueller, MD, PhD is a board-certified neurologist, pediatrician and neuro-oncologist with a research program focused on novel therapies for pediatric gliomas and other malignant brain tumors. She is a Professor of Neurology, Neurosurgery and Pediatrics at the University of California, San Francisco (UCSF) and a Professor of Pediatrics at the University of Zurich, Switzerland. She received her PhD in the Department of Biochemistry in Hamburg, Germany generating gene expression libraries for adult glioblastomas for target identification. Prof. Mueller completed her clinical training in Boston as well as at UCSF. Within the Brain Tumor Research Center located in the Helen Diller Cancer Center at UCSF, she conducts preclinical studies in pediatric brain tumor models to support the rationale for the design of early phase clinical trials for children with brain tumors with a specific focus on children with diffuse midline gliomas (DMGs). On the translational site, she is leading the Pacific Pediatric Neuro-Oncology Consortium (www.pnoc.us) – a now 22 US based-member institution clinical trial consortium with international expansion (Zurich, Switzerland; Australia; Israel and Netherlands) dedicated to developing new therapies for pediatric and AYA brain tumor patients. She also serves as the clinical lead of the DMG Centre at the Children’s Hospital of Zurich, Switzerland. Together with Dr. Nazarian she is also leading the DMG working group of PNOC. Prof. Mueller has extensive experience in bringing new agents into the clinic-chairing or co-chairing over 15 clinical, multi-center trials and leading large multi-centers studies. She has supervised many multi-site tumor boards and is overseeing the Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma National Brain Tumor Board.

To be evaluated for the DIPG DMG National Brain Tumor Board, please complete the following information. Our coordinator will contact the patient provider within three business days of submittal.